Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma - A Gynecologic Oncology Group Study

Frederick B. Stehman, John A. Blessing, Howard D. Homesley, John L. Currie, Edgardo L. Yordan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In an on-going Phase II evaluation, dianhydrogalactitol (NSC 132313) was administered intravenously to 28 patients with advanced or recurrent non-squamous cell carcinoma of the cervix. The initial dosage was 60 mg/m2/wk with escalation to 75 mg/m2/wk if there were no adverse effects. Twenty-seven patients were evaluable for toxicity and response. There was one complete response and one partial response. Adverse effects were not infrequent but tolerable.

Original languageEnglish (US)
Pages (from-to)331-333
Number of pages3
JournalInvestigational New Drugs
Volume2
Issue number3
DOIs
StatePublished - Sep 1 1984

Fingerprint

Dianhydrogalactitol
Carcinoma
Cervix Uteri
Therapeutics

Keywords

  • cervix
  • dianhydrogalactitol
  • galactitol
  • non-squamous-chemotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma - A Gynecologic Oncology Group Study. / Stehman, Frederick B.; Blessing, John A.; Homesley, Howard D.; Currie, John L.; Yordan, Edgardo L.

In: Investigational New Drugs, Vol. 2, No. 3, 01.09.1984, p. 331-333.

Research output: Contribution to journalArticle

Stehman, Frederick B. ; Blessing, John A. ; Homesley, Howard D. ; Currie, John L. ; Yordan, Edgardo L. / Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma - A Gynecologic Oncology Group Study. In: Investigational New Drugs. 1984 ; Vol. 2, No. 3. pp. 331-333.
@article{5eca090a13ba4ca58436ccbb3475a90f,
title = "Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma - A Gynecologic Oncology Group Study",
abstract = "In an on-going Phase II evaluation, dianhydrogalactitol (NSC 132313) was administered intravenously to 28 patients with advanced or recurrent non-squamous cell carcinoma of the cervix. The initial dosage was 60 mg/m2/wk with escalation to 75 mg/m2/wk if there were no adverse effects. Twenty-seven patients were evaluable for toxicity and response. There was one complete response and one partial response. Adverse effects were not infrequent but tolerable.",
keywords = "cervix, dianhydrogalactitol, galactitol, non-squamous-chemotherapy",
author = "Stehman, {Frederick B.} and Blessing, {John A.} and Homesley, {Howard D.} and Currie, {John L.} and Yordan, {Edgardo L.}",
year = "1984",
month = "9",
day = "1",
doi = "10.1007/BF00175387",
language = "English (US)",
volume = "2",
pages = "331--333",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma - A Gynecologic Oncology Group Study

AU - Stehman, Frederick B.

AU - Blessing, John A.

AU - Homesley, Howard D.

AU - Currie, John L.

AU - Yordan, Edgardo L.

PY - 1984/9/1

Y1 - 1984/9/1

N2 - In an on-going Phase II evaluation, dianhydrogalactitol (NSC 132313) was administered intravenously to 28 patients with advanced or recurrent non-squamous cell carcinoma of the cervix. The initial dosage was 60 mg/m2/wk with escalation to 75 mg/m2/wk if there were no adverse effects. Twenty-seven patients were evaluable for toxicity and response. There was one complete response and one partial response. Adverse effects were not infrequent but tolerable.

AB - In an on-going Phase II evaluation, dianhydrogalactitol (NSC 132313) was administered intravenously to 28 patients with advanced or recurrent non-squamous cell carcinoma of the cervix. The initial dosage was 60 mg/m2/wk with escalation to 75 mg/m2/wk if there were no adverse effects. Twenty-seven patients were evaluable for toxicity and response. There was one complete response and one partial response. Adverse effects were not infrequent but tolerable.

KW - cervix

KW - dianhydrogalactitol

KW - galactitol

KW - non-squamous-chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0021167003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021167003&partnerID=8YFLogxK

U2 - 10.1007/BF00175387

DO - 10.1007/BF00175387

M3 - Article

C2 - 6511240

AN - SCOPUS:0021167003

VL - 2

SP - 331

EP - 333

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -